- Location
Galectin
"-
Galectin Therapeutics Has Reported a Net Loss of $2.54m,or $0.72 Per Share
Aug 19, 2013Galectin Therapeutics has reported a net loss of $2.54m, or $0.72 per share, for the second quarter ended on 30 June 2013 compared to a net loss of $2.66m, or $0.19 per share, in 2012. Total operating loss for the second quarter ended 30 ...
-
CE Mark to Bg Medicine Automated Galectin-3 Blood Test Is Granted by EU
Jan 5, 2013BG Medicine has obtained CE mark certification for its automated Galectin-3 blood test, designed for the management of chronic heart failure. The test will be made available through bioMerieux's VIDAS immunoassay, which consists of about ...
Tags: EU, CE Mark, BG Medicine, Medicine
-
Galectin-3 Testing Services of BG Medicine are distributed by Atherotech
Dec 19, 2012Atherotech Diagnostics Lab, a CLIA-certified clinical reference laboratory, has entered into an agreement to offer BG Medicine's galectin-3 testing services to laboratory customers and physicians. To offer the services, Atherotech is ...
-
BG Medicine Has Registered a 510(K) Premarket Notification with The US FDA
Dec 7, 2012BG Medicine has registered a 510(k) premarket notification with the US Food and Drug Administration (FDA) for approval of its Architect Galectin-3 assay. The Architect Galectin-3 assay, which is designed for use with Abbott's automated ...
Tags: BG Medicine, premarket notification, FDA, Architect Galectin-3 assay
-
BG Medicine Has Filed 510(K) Premarket Notification
Dec 5, 2012BG Medicine has filed 510(k) premarket notification for regulatory clearance of an expanded indication for its BGM Galectin-3 test with the FDA. The blood test is at present indicated for use in patients with chronic heart failure who are ...
Tags: BG Medicine, blood test, heart failure
-
BG Medicine Filed a 510(K) Premarket Notification for ARCHITECT Galectin-3 Assay
Dec 5, 2012Cardiovascular diagnostics developer BG Medicine has filed a 510(k) Premarket Notification with the US Food and Drug Administration (FDA) for regulatory clearance for the ARCHITECT Galectin-3 assay. Used with Abbott's fully automated ...
-
BG Medicine Has Announced The Availability of Galectin-3 Testing Services
Dec 5, 2012BG Medicine has announced the availability of galectin-3 testing services through Atherotech Diagnostics Lab. Atherotech leverages BGM Galectin-3 test to offer galectin-3 testing. The BGM Galectin-3 test was cleared as an aid in ...
-
Galectin Therapeutics Will Move Its Corporate Offices to Atlanta, Georgia, US
Nov 29, 2012Galectin Therapeutics will move its corporate offices to Atlanta, Georgia, US, by 1 October 2012 while maintaining a laboratory-based effort in the Boston area. The move will bring Galectin Therapeutics closer to its collaborator, Complex ...
Tags: galectin therapeutics, atlanta, collaborator
-
USPTO Grants Galectin Therapeutics a Notice of Issuance for a Patent
Jul 24, 2012The USPTO has granted Galectin Therapeutics a notice of issuance for a patent covering methods of derivation and use for carbohydrate-based galectin inhibitor compound for use in patients with chronic liver disease associated with the ...
Tags: Galectin, US patent, disease therapy
